Spotlight On... Johns Hopkins developing thought-controlled robotic arm with help of wearable armband; Spreemo poaches Philips big data scientist; AtriClip is launched in Japan; and more...

Johns Hopkins University is developing a prosthetic arm that can be controlled by thought. It is enabled by the $200 Myo wearable armband, which sends electrical impulse data to a computer. In turn, the computer interprets the information and tells the prosthetic arm to complete the task. "The APL (Applied Physics Lab) arm is the most unique arm I've ever worn," said Johnny Matheny, who does not have part of his arm due to cancer. "It has the ability to do anything that your natural hand, wrist or shoulder can do." More

@FierceMedDev: IBM bets its future on machine learning and Watson Health. More | Follow @FierceMedDev

@VarunSaxena2: Interesting article in @TheEconomist. Which lifesci hub do you think is no. 1? Poll | Follow @VarunSaxena2

@EmilyWFierce: Roche blindsided by off-label Avastin fallout in #India. Story | Follow @EmilyWFierce

> New York City-based healthcare analytics startup Spreemo has hired Daniel Elgort as its VP of Healthcare Analytics. He was previously the director and global lead of healthcare big data analytics research at Royal Philips ($PHG). More

> AtriCure ($ATRC) has launched its AtriClip in Japan to treat left atrial appendage occlusion. More

> Glaukos ($GKOS) presented positive 3-year data for its Glaukos iStent Trabecular Micro-Bypass Stent in combination with cataract surgery. More

Biotech News

@FierceBiotech: Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent. Report | Follow @FierceBiotech

@JohnCFierce: Seeing some silly reactions to $ZFGN this a.m. No trial that ends in a complete hold is a "success," and efficacy data won't lift that hold. | Follow @JohnCFierce

@DamianFierce: Index Ventures' official Dick Costolo announcement is a link to his tweets of screenshots from his notes app. Website | Follow @DamianFierce

> Bristol-Myers moves forward with its $1.2B CytomX alliance. Item

> Surrounded by top scientists, Biden hustles up support for accelerated cancer R&D. Article

Pharma News

@FiercePharma: Roche blindsided by off-label Avastin fallout in India. More | Follow @FiercePharma

@CarlyHFierce: ICYMI: Big question for Pfizer: Will Enbrel's EU biosim bring on the pain? Story | Follow @CarlyHFierce

> Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals. More

> NHS watchdog takes issue with Pfizer exec's new role on foundation trust's board. News

> Pfizer looks to Russian partnership to produce some of its meds there, report says. Story

Biotech Research News

> New study offers researchers a guide to making next-gen TB drugs. More

> Allergan highlights preclinical evidence of cognitive safety for fast-acting depression drug. News

> Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals. Story

> Columbia U. team refines replacement cells for injured hearts. Article

> Study presents a fresh opportunity for early ovarian cancer diagnosis. Report

Pharma Marketing News

> Glass half empty? Pharma staffers about as content as average Americans, survey finds. Story

> Pharma's December TV spending sags; Pfizer and BMS' Eliquis rises to top. News

> Takeda's U.K. unit brings sales force in-house to boost efforts in oncology, IBD. Report

> Merck & Co. sues Merck KGaA over naming rights in transatlantic tug-of-war. Article

> Minds + Assembly jumps off big pharma agencies, aims for 'breakthrough' work with Orexo. More

Vaccines News

> Merck to submit Ebola vaccine for regulatory approval in 2017. Story

> FDA expands indication for GSK's Hib vaccine, Hiberix. News

> Dengue vaccine developed at NIH enters PhIII in Brazil. More

> Baltimore's Profectus BioSciences starts PhI trial of Ebola vaccine. Report

> Sanofi working with health authorities on dengue vaccine strategies. Article

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.